See more : Palco Metals Limited (PALCO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of CombiGene AB (publ) (COMBI.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CombiGene AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- PGF Polska Grupa Fotowoltaiczna SA (PGV.WA) Income Statement Analysis – Financial Results
- Tilray Brands, Inc. (2HQ.DE) Income Statement Analysis – Financial Results
- Gurit Holding AG (GUR.SW) Income Statement Analysis – Financial Results
- Akerna Corp. (KERN) Income Statement Analysis – Financial Results
- Imperalis Holding Corp. (IMHC) Income Statement Analysis – Financial Results
CombiGene AB (publ) (COMBI.ST)
About CombiGene AB (publ)
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.54M | 26.70M | 84.04M | 10.83M | 14.99M | 8.15K | 3.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.83M | 45.90M | 68.88M | 2.49M | 1.17M | 16.92M | 12.41M | 7.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -21.29M | -19.20M | 15.16M | 8.33M | 13.82M | -16.91M | -9.41M | -7.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -384.02% | -71.91% | 18.04% | 76.96% | 92.22% | -207,566.13% | -313.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 54.59M | 29.64M | 25.26M | 15.05M | 10.11M | 7.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.87M | 13.03M | 54.59M | 29.64M | 25.26M | 15.05M | 10.11M | 7.25M | 6.25M | 961.36K | 27.49K | 9.76K |
| Other Expenses | 0.00 | 46.66M | 8.86M | -279.04K | -6.83M | -1.81M | 1.85M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 18.77M | 46.66M | 63.45M | 29.36M | 18.44M | 13.24M | 11.96M | 8.67M | 6.25M | 961.36K | 27.50K | 9.76K |
| Cost & Expenses | 44.14M | 46.66M | 63.45M | 29.36M | 18.44M | 13.24M | 11.96M | 8.67M | 6.25M | 961.36K | 27.50K | 9.76K |
| Interest Income | 2.94M | 791.83K | 24.00 | 5.00 | 237.04K | 415.75K | 0.00 | 121.00 | 2.42K | 861.00 | 0.00 | 2.05K |
| Interest Expense | 4.80K | 1.68K | 0.00 | 1.39M | 237.04K | 381.16K | 111.00 | 91.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 329.34K | 300.00K | 2.59M | 2.49M | 1.17M | 13.23M | 8.96M | 8.67M | 6.47M | 961.36K | 27.49K | 9.76K |
| EBITDA | -35.34M | -5.86M | 23.56M | -25.66M | -16.53M | 83.69K | -111.00 | 30.00 | 2.42K | 861.00 | -10.00 | -2.05K |
| EBITDA Ratio | -637.36% | -13.34% | 28.03% | -237.03% | -110.27% | -156,701.51% | -298.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.31M | -6.95M | 20.96M | -28.16M | -17.69M | -13.18M | -8.96M | -8.67M | -6.25M | -961.36K | -27.49K | -9.76K |
| Operating Income Ratio | -654.84% | -26.02% | 24.95% | -260.07% | -118.05% | -161,805.19% | -298.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 639.76K | 11.01M | 24.00 | -2.49M | -659.26K | 83.69K | -111.00 | 30.00 | 2.41K | 861.00 | -10.00 | -2.05K |
| Income Before Tax | -35.67M | -6.16M | 20.96M | -29.55M | -17.93M | -13.15M | -8.96M | -8.67M | -6.25M | -960.50K | -27.50K | -11.81K |
| Income Before Tax Ratio | -643.30% | -23.06% | 24.95% | -272.93% | -119.64% | -161,380.65% | -298.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -790.14K | 2.36M | 1.22M | -89.30K | 303.72K | -8.96M | -8.67M | 2.41K | 861.00 | -10.00 | -2.05K |
| Net Income | -35.67M | -5.37M | 20.96M | -30.77M | -17.84M | -13.15M | -8.96M | -8.67M | -6.47M | -960.50K | -27.50K | -11.81K |
| Net Income Ratio | -643.30% | -20.10% | 24.95% | -284.23% | -119.04% | -161,380.65% | -298.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.80 | -0.27 | 1.21 | -3.34 | -6.01 | -9.78 | -11.30 | -8.08 | -6.09 | -2.17 | -0.10 | -0.06 |
| EPS Diluted | -1.80 | -0.27 | 1.21 | -3.34 | -6.01 | -9.47 | -10.95 | -8.08 | -6.09 | -2.17 | -0.10 | -0.06 |
| Weighted Avg Shares Out | 19.80M | 19.80M | 17.31M | 9.23M | 2.97M | 1.34M | 792.67K | 1.07M | 1.06M | 442.20K | 287.20K | 205.20K |
| Weighted Avg Shares Out (Dil) | 19.80M | 19.80M | 17.31M | 9.23M | 2.97M | 1.39M | 818.19K | 1.07M | 1.06M | 442.20K | 287.20K | 205.20K |
Source: https://incomestatements.info
Category: Stock Reports